These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29700168)

  • 1. Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy.
    Galli M; Chatterjee M; Grasso M; Specchia G; Magen H; Einsele H; Celeghini I; Barbieri P; Paoletti D; Pace S; Sanderson RD; Rambaldi A; Nagler A
    Haematologica; 2018 Oct; 103(10):e469-e472. PubMed ID: 29700168
    [No Abstract]   [Full Text] [Related]  

  • 2. Roneparstat: Development, Preclinical and Clinical Studies.
    Noseda A; Barbieri P
    Adv Exp Med Biol; 2020; 1221():523-538. PubMed ID: 32274725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.
    Pala D; Rivara S; Mor M; Milazzo FM; Roscilli G; Pavoni E; Giannini G
    Glycobiology; 2016 Jun; 26(6):640-54. PubMed ID: 26762172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis.
    Borsig L
    Semin Thromb Hemost; 2007 Jul; 33(5):540-6. PubMed ID: 17629852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.
    Ramani VC; Zhan F; He J; Barbieri P; Noseda A; Tricot G; Sanderson RD
    Oncotarget; 2016 Jan; 7(2):1598-607. PubMed ID: 26624982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.
    Rossini A; Zunino F; Ruggiero G; De Cesare M; Cominetti D; Tortoreto M; Lanzi C; Cassinelli G; Zappasodi R; Tripodo C; Gulino A; Zaffaroni N; Di Nicola M
    Hematol Oncol; 2018 Feb; 36(1):360-362. PubMed ID: 28730742
    [No Abstract]   [Full Text] [Related]  

  • 7. Heparanase 1: a key participant of inner root sheath differentiation program and hair follicle homeostasis.
    Malgouries S; Donovan M; Thibaut S; Bernard BA
    Exp Dermatol; 2008 Dec; 17(12):1017-23. PubMed ID: 18557927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
    Gerber U; Hoß SG; Shteingauz A; Jüngel E; Jakubzig B; Ilan N; Blaheta R; Schlesinger M; Vlodavsky I; Bendas G
    Semin Thromb Hemost; 2015 Mar; 41(2):244-54. PubMed ID: 25682080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.
    Cassinelli G; Favini E; Dal Bo L; Tortoreto M; De Maglie M; Dagrada G; Pilotti S; Zunino F; Zaffaroni N; Lanzi C
    Oncotarget; 2016 Jul; 7(30):47848-47863. PubMed ID: 27374103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.
    Borgenström M; Wärri A; Hiilesvuo K; Käkönen R; Käkönen S; Nissinen L; Pihlavisto M; Marjamäki A; Vlodavsky I; Naggi A; Torri G; Casu B; Veromaa T; Salmivirta M; Elenius K
    Semin Thromb Hemost; 2007 Jul; 33(5):547-56. PubMed ID: 17629853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new approach to glycan targeting: enzyme inhibition by oligosaccharide metalloshielding.
    Mangrum JB; Engelmann BJ; Peterson EJ; Ryan JJ; Berners-Price SJ; Farrell NP
    Chem Commun (Camb); 2014 Apr; 50(31):4056-8. PubMed ID: 24463939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparinase-II-catalysed degradation of N-propionylated heparin.
    Moffat CF; Long WF; McLean MW; Williamson FB
    Biochem Soc Trans; 1997 Nov; 25(4):S654. PubMed ID: 9450082
    [No Abstract]   [Full Text] [Related]  

  • 13. Eosinophil major basic protein: first identified natural heparanase-inhibiting protein.
    Temkin V; Aingorn H; Puxeddu I; Goldshmidt O; Zcharia E; Gleich GJ; Vlodavsky I; Levi-Schaffer F
    J Allergy Clin Immunol; 2004 Apr; 113(4):703-9. PubMed ID: 15100677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total synthesis of CRM646-A and -B, two fungal glucuronides with potent heparinase inhibition activities.
    Wang P; Zhang Z; Yu B
    J Org Chem; 2005 Oct; 70(22):8884-9. PubMed ID: 16238322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat.
    Alekseeva A; Mazzini G; Giannini G; Naggi A
    Carbohydr Polym; 2017 Jan; 156():470-480. PubMed ID: 27842848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas.
    Cassinelli G; Zaffaroni N; Lanzi C
    Cancer Lett; 2016 Nov; 382(2):245-254. PubMed ID: 27666777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
    MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
    Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connective tissue activation XXXVIII: heparin/heparanase activity of human platelets resides in a high molecular weight protein, not in connective tissue activating peptide III.
    Castor CW; Kotlyar A; Edwards BE
    J Rheumatol; 2002 Nov; 29(11):2337-44. PubMed ID: 12415589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
    Viziteu E; Klein B; Basbous J; Lin YL; Hirtz C; Gourzones C; Tiers L; Bruyer A; Vincent L; Grandmougin C; Seckinger A; Goldschmidt H; Constantinou A; Pasero P; Hose D; Moreaux J
    Leukemia; 2017 Oct; 31(10):2104-2113. PubMed ID: 28186131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorimetric heparinase assay for alternative anti-metastatic activity.
    Ahn SC; Kim BY; Oh WK; Park YM; Kim HM; Ahn JS
    Life Sci; 2006 Sep; 79(17):1661-5. PubMed ID: 16806278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.